JPM 2022: Sarepta projects Duchenne muscular gene therapy will go to FDA next year, sees shares crash 15%
JPM 2022: Sarepta projects Duchenne muscular gene therapy will go [...]
JPM 2022: Moderna finds Carisma’s macrophage tech compelling enough for $45M cancer research deal
JPM 2022: Moderna finds Carisma’s macrophage tech compelling enough for [...]
BioMarin’s hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts
BioMarin’s hemophilia A gene therapy hits goal in phase 3, [...]
Maze Therapeutics navigates $190M financing round as it plots course to the clinic
Maze Therapeutics navigates $190M financing round as it plots course [...]
Merck leans into AI with $610M in biobucks for Absci drug discovery pact
Merck leans into AI with $610M in biobucks for Absci [...]
Atea sticks it out with failed COVID-19 antiviral but also raids Merck’s store room for hepatitis C drug
Atea sticks it out with failed COVID-19 antiviral but also [...]
Cytokinetics finds worldwide partner in Royalty Pharma for heart failure drug, snags up to $450M to extend runway
Cytokinetics finds worldwide partner in Royalty Pharma for heart failure [...]
AstraZeneca picks up new weapon in rare disease fight with Alnylam and Pfizer, paying $30M for rights to an early-phase asset
AstraZeneca picks up new weapon in rare disease fight with [...]
Chutes & Ladders—Maraganore’s post-Alnylam ambitions take flight
Chutes & Ladders—Maraganore’s post-Alnylam ambitions take flight fkansteiner Thu, 01/06/2022 [...]
Aligos says stop right now to lead hep B med after fruitless phase 1 data
Aligos says stop right now to lead hep B med [...]